Table 1 Descriptive data concerning survival (in days) as well as distribution of anti-p53 antibodies for investigated clinical parameters. The reported p-values relates to survival according to univariate analysis for the investigated clinical parameters
Variables | Number of patients | Median Surv (days) | SD* | Anti p53 abs Median/Range | P-value |
|---|---|---|---|---|---|
Gender | 0.75 | ||||
Male | 62 | 330 | 582 | 0.08 (0–140) | |
Female | 22 | 363 | 257 | 0.1 (0–32) | |
Stage | 0.63 | ||||
3a | 47 | 324 | 660 | 0.02 (0–140) | |
3b | 25 | 332 | 203 | 0.23 (0–43) | |
4 | 12 | 383 | 226 | 0.04 (0–25) | |
Performance status | 0.77 | ||||
0 | 53 | 312 | 286 | 0.04 (0–43) | |
1 | 21 | 359 | 392 | 0.23 (0–140) | |
2 | 8 | 319 | 160 | 0.3 (0–32) | |
Smoking | 0.29 | ||||
Yes | 53 | 387 | 339 | 0.05 (0–140) | |
Ex-smoker | 22 | 294 | 228 | 0.24 (0–43) | |
No | 5 | 290 | 158 | 0.12 (0–6) | |
Weight reduction. kg | 0.78 | ||||
Yes | 42 | 348 | 293 | 0.20 (0–140) | |
No | 21 | 281 | 317 | 0.0 (0–10) | |
Histology | 0.73 | ||||
Squamous carcinoma | 59 | 324 | 321 | 0.08 (0–140) | |
Adenocarcinoma | 23 | 347 | 839 | 0.12 (0–25) | |
Bronchioalv. ca | 2 | 452 | 375 | 0.03 (0–0.05) | |
Tumour volume (recist) | 0.007 | ||||
<50 | 18 | 446 | 433 | 0.04 (0–6) | |
>50 | 21 | 290 | 142 | 0.22 (0–140) | |
Subjective improvement | 0.95 | ||||
Yes | 41 | 306 | 333 | 0.12 (0–140) | |
No | 11 | 306 | 146 | 0 (0–32) | |
Objective improvement | 0.73 | ||||
Stable disease | 5 | 551 | 371 | 0.06 (0–13) | |
Regress of tumour | 3 | 684 | 252 | 0 (0–0) | |
Progress of tumour | 2 | 526 | 333 | 0.55 (0–1.1) | |
Anti-p53 antibodies | 0.29 | ||||
Continuous | |||||
Anti-p53 antibodies index | 0.96 | ||||
neg | 68 | 334 | 543 | ||
intermediate | 2 | 486 | 390 | ||
pos | 14 | 330 | 410 |